Brown Advisory
LYEL icon

Brown Advisory’s Lyell Immunopharma LYEL Stock Holding History

Brown Advisory’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,999
Closed -$4.18M – 1190
2021
Q4 		$4.18M Buy
26,999
+4,160
+18% +$928K 0.01% 503
2021
Q3 		$6.76M Buy
+22,839
New +$6.84M 0.01% 422

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory's LYEL Position: Q1 2022 in Review

Brown Advisory sold out of Lyell Immunopharma (LYEL) in Q1 2022, closing a stake of 26,999 shares — an estimated $4.18M sold.

Brown Advisory first reported a position in LYEL in Q3 2021 and held it in 2 quarters. The position peaked at $6.76M in Q3 2021. 79 funds tracked by Wall St. Rank hold LYEL as of Q1 2022.

  • Brown Advisory reported no remaining Lyell Immunopharma position as of Q1 2022 after selling out during the quarter.
  • Brown Advisory sold 26,999 Lyell Immunopharma shares in Q1 2022, an estimated $4.18M.
  • Brown Advisory first reported a position in Lyell Immunopharma in Q3 2021 and held it in 2 quarters.
  • Brown Advisory's Lyell Immunopharma position peaked at $6.76M in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2022.

Based on Brown Advisory's 13F filing for Q1 2022, filed 9 May 2022.